Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

Opinion|Videos|January 31, 2025

Patient Selection for Aflibercept 8 mg

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

Episodes in this series

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 2 Advantages of the molecular structure of aflibercept

EP. 2 Advantages of the molecular structure of aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 10 Safety Profile of New Therapies

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

Who is the ideal patient for aflibercept 8 mg?

Newsletter

Don’t miss out—get Modern Retina updates delivered straight to your inbox.

Related Content

AMD lookback: Highlights from June 2026

ByKassi Filkins

July 10th 2026

Cynthia Toth, MD, of the Duke Department of Ophthalmology

Using OCT to predict neurodevelopmental risk in preterm infants: Cynthia Toth, MD

ByCytnthia Toth, MD,Lucia Gambuzza,Abigail Lewis, Content Intern

July 8th 2026

(Modern Retina) Could FLIO predict how fast geographic atrophy will grow?

Could FLIO predict how fast geographic atrophy will grow?

ByModern Retina Staff

July 4th 2026

(Modern Retina) Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

ByModern Retina Staff

July 3rd 2026

(Image credit: Modern Retina) Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

ByModern Retina Staff

June 30th 2026

Latest CME

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

John Kitchens, MD

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

(COPE Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(COPE Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

Trending on Eye Care Network - Ophthalmology Times

FDA approves subcutaneous Enspryng for TED

AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA

OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant

EC-104 outperforms Ozurdex in phase 2 BETTIS-1 trial for anti-VEGF–resistant DME

Introducing Noah Banoub: The medical student’s path from church pews to the retina clinic